Published June 25, 2021 | Version v1
Preprint Open

Early Treatment of the Inflammatory Stage of COVID-19 and its rationale

  • 1. Family Practice Oncology Network, British Columbia Cancer Agency (retired), Prince George, BC, V2M 7E9, Canada
  • 2. Department of Animal Biosciences, University of Guelph, Guelph, ON, N1G 2W1, Canada
  • 3. Department of Biochemistry, University of Toronto, Toronto, ON, M5S 1A8, Canada
  • 4. Department of Pharmacology & Toxicology, Queen's University, Kingston, ON, K7L 3N6, Canada



  COVID-19 is typically an acute infection caused by SARS-CoV-2 virus that lasts 2-3 weeks. However, in some instances the disease may worsen and lead to Acute Respiratory Distress Syndrome (ARDS) and multisystem damage that can result in long term disability or even death if not treated early and effectively.

  This article focuses on the early inflammatory phase of COVID-19, which typically starts about a week after the onset of first symptoms associated with the initial viral stage. A readily accessible treatment option comprising well-known glucocorticoids, antihistamines, leukotriene antagonists and anticoagulants is included, and its rationale is given. This treatment option is especially relevant for general practitioners and emergency room clinicians and can be initiated prior to the need for hospitalization and in most cases may also prevent it.


Early Treatment of the Inflammatory Stage of COVID-19 and its rationale.pdf

Files (311.1 kB)

Additional details

Related works

Journal article: 10.31083/j.rcm.2020.04.264 (DOI)
Journal article: 10.1016/S2213-2600(21)00160-0 (DOI)
Journal article: 10.24875/aidsrev.200001261 (DOI)